TG and thyroid cancer: In addition, cfRNA will address the issue of anti-thyroglobulin antibodies (present in 25% of thyroid cancer patients), that affects the reliability of thyroglobulin immunoassay (Giovanella et al., 2011; Spencer, 2011).